

Ibopamine 2% eye drops in the treatment of patients with ocular hypotony after vitreoretinal surgery for retinal detachment or uveitis: results after six months of treatment

Submission date 20/12/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 20/12/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 12/04/2021	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr J C van Meurs

Contact details
Oogziekenhuis Rotterdam
Schiedamsevest 180
Rotterdam
Netherlands
3011 BH
+31 (0)10 401 7777
vanMeurs@oogziekenhuis.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

OZR-2003-16

Study information

Scientific Title

Ibopamine 2% eye drops in the treatment of patients with ocular hypotony after vitreoretinal surgery for retinal detachment or uveitis: results after six months of treatment

Study objectives

Long-term administration of Ibopamine hydrochloride eye drops restores and maintains intraocular pressure in patients with hypotony following vitreoretinal surgery for ablatio reinae, or uveitis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Non-randomised trial

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Ocular hypotony following either vitreoretinal surgery or uveitis

Interventions

Long-term topical treatment with Ibopamine (2%) eye drops.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Ibopamine

Primary outcome measure

1. Ocular pressure
2. Vision

Secondary outcome measures

1. Position of silicone oil (after surgery)
2. Patients comfort/pain five minutes after eye drops administration

Overall study start date

01/03/2004

Completion date

01/03/2006

Eligibility

Key inclusion criteria

1. Hypotony (0-5 mm Hg)
2. Stable eye pressure for at least 4 months
3. No reaction of eye pressure to atropine and steroids
4. Continued steroid treatment during past six months
5. Status after vitreoretinal surgery or uveitis

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

21 (Study closed, analysis & publication in progress)

Total final enrolment

17

Key exclusion criteria

1. Chronic heart failure
2. Hypotony caused by other factors than surgery or uveitis
3. Traction on corpus ciliare
4. Cyclodialysis

Date of first enrolment

01/03/2004

Date of final enrolment

01/03/2006

Locations

Countries of recruitment

Netherlands

Study participating centre

Oogziekenhuis Rotterdam

Rotterdam

Netherlands

3011 BH

Sponsor information

Organisation

Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)

Sponsor details

Schiedamsevest 180

Rotterdam

Netherlands

3011 BH

+31 (0)10 401 77 77

info@oogziekenhuis.nl

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/02hjc7j46>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Foundation of Scientific Research at the Eye Hospital (Stichting Wetenschappelijk Onderzoek het Oogziekenhuis) (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/04/2012	12/04/2021	Yes	No